Key result
Single-injection enoxaparin matches split dosing for dialyzer fiber patency during nocturnal hemodialysis.
Why the study?
During extended nocturnal hemodialysis, low-molecular-weight heparin can be given as a single injection or divided doses, and it was uncertain whether a single injection suffices to maintain dialyzer fiber patency and whether anti-Xa levels predict fiber blocking.
Does a single injection of enoxaparin at the start of extended nocturnal hemodialysis maintain post-dialysis dialyzer fiber patency as effectively as a divided two-injection regimen in stable maintenance hemodialysis patients?
RCT (n=20)
Randomized cross-over via www.randomizer.org
No
Does a single injection of enoxaparin at the start of extended nocturnal hemodialysis maintain post-dialysis dialyzer fiber patency as effectively as a divided two-injection regimen in stable maintenance hemodialysis patients?
A single predialysis bolus of enoxaparin is sufficient to maintain dialyzer fiber patency during 8-hour nocturnal hemodialysis compared to split dosing, reducing nursing workload and patient sleep disruption, while plasma anti-Xa monitoring fails to predict actual fiber clotting.
Answers are grounded in this paper and cite their sources.
Supports single-bolus enoxaparin in nocturnal hemodialysis to cut workload and interruptions; confirms comparable dialyzer patency versus split dosing.
Background: During extended (nocturnal) hemodialysis (ENHD), the dose of low-molecular-weight heparin (LMWH) can be administered as a single injection or as a divided dose over different time points. Our hypothesis was that a single injection might be sufficient to maintain dialyzer fiber patency. In addition, we investigated whether the biochemical clotting parameter anti-Xa accurately predicts fiber blocking. Methods: Our hypothesis was tested in 20 stable patients on ENHD in a random cross-over setting during two consecutive midweek sessions. The regular total dose of LMWH (i.e. enoxaparin, Clexane® 40-100 mg, Sanofi, Belgium) was either given (i) in a single injection at the dialysis start or (ii) divided over two injections, at the start and halfway the dialysis session. Blood samples were taken from the arterial blood line at different time points to determine plasma anti-Xa activity levels. Post-dialysis, the rinsed and dried hemodialyzers were scanned with a reference micro-computed tomography (µCT) scanning technique, and non-blocked fibers were counted in a central cross-section of the dialyzer outlet potting (ImageJ, NIH, USA). Results: The percentage of open fibers in the dialyzers after a single injection of LMWH [91 (61-96)%] versus divided administration [94 (79-98)%] was not different. Time averaged anti-Xa activity levels were clinically not significantly different between both sessions. Anti-Xa activity levels correlated with the administered anticoagulation doses normalized for body weight, but not with the percentages open fibers in the dialyzers. Conclusion: Our results indicate that there is no need to administer enoxaparin over two injections for ENHD up to 8 h. The usefulness of monitoring anti-Xa levels to predict fiber patency, assessed by µCT, can be questioned, but further clinical trials are needed.
No takes yet. Share an insight, caveat, or question.
Thielemans et al. (2023) conducted an RCT in Maintenance extended (nocturnal) hemodialysis (ENHD) (n=20). Enoxaparin single injection at dialysis start vs. Enoxaparin divided over two injections (at dialysis start and halfway through the session: 20+20, 40+20, 40+40, or 60+40 mg) was evaluated on Percentage of open dialyzer fibers post-dialysis (at 70% open fiber area threshold) quantified by micro-computed tomography (µCT) (p=0.235). Single-injection enoxaparin maintained comparable post-dialysis dialyzer open fiber percentage to split-dose administration during 8-hour nocturnal hemodialysis.
Synapse has enriched 10 related papers. Consider them for comparative context: